Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein

Circulation

Volumn 97, Issue 9, 1998, Pages 865-870

  Medina, Pascual ^b   Acuña, Antonio ^b   Martínez León, Juan B ^b   Otero, Eduardo ^b   Vila, José M ^b   Aldasoro, Martín ^b   Lluch, Salvador ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NONE

Author keywords

Arginine vasopressin; Electrical stimulation; Norepinephrine; Veins

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; CALCIUM CHANNEL; DESMOPRESSIN; DIHYDROPYRIDINE DERIVATIVE; NIFEDIPINE; NORADRENALIN; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 ISOLEUCINE 4 ISOLEUCINE 8 ARGININE]; VASOTOCIN DERIVATIVE; VASOTOCIN[2 PHENYLALANINE 8 ORNITHINE];

ADRENERGIC TRANSMISSION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; VASCULAR RING; VENOCONSTRICTION;

EID: 0032502288     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.9.865     Document Type: Article

References (36)

1. Michell RM, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979;7:861-865.
2. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic muscle cells in culture. Am J Physiol. 1983;244:E72-E82.
3. Thibonnier M. Use of vasopressin antagonists in human diseases. Kidney Int. 1988;34:S48-S51.
4. Ohlstein EH, Berkowitz BA. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther. 1986;239:737-741.
5. Martínez MC, Vila JM, Aldasoro M, Medina P, Flor B, Lluch S. Relaxation of human isolated mesenteric arteries by vasopressin and desmopresin. Br J Pharmacol. 1994;113:419-424.
6. Lluch S, Conde MV, Diéguez G, López de Pablo AL, González MC, Estrada C, Gómez B. Evidence for the direct effect of vasopressin on human and goat cerebral arteries. J Phamatol Exp Ther. 1984;228:749-755.
7. White RP, Robertson JT, Pharmacodynamic evaluation of human cerebral arteries in the genesis of vasospasm. Neurosurgery. 1987;21:523-531.
8. Medina P, Vila JM, Martínez MC, Aldasoro M, Chuan P, Lluch S. Effects of vasopressin on human renal arteries. Eur J Clin Invest. 1996;26:966-972.
9. Martín de Aguilera E, Vila JM, Irurzun A, Martínez MC, Martínez Cuesta MA, Lluch S. Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke. 1990;21:1689-1693.
10. Martínez MC, Aldasoro M, Vila JM, Medina P, Lluch S. Responses to vasopressin and desmopressin of human cerebral arteries. J Pharmacol Exp Ther. 1994;270:622-627.
11. Liard JF, Spadone JC. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs. J Cardiovasc Pharmacol. 1984;6:713-719.
12. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Hemodynamic and coagulation responses to 1-desamino 8-D-arginine vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J. Med. 1988;18:881-887.
13. 2 receptor. J Clin Invest. 1989;84:418-426.
14. 2 receptor-mediated vasodilation in healthy humans. J Cardiovasc Pharmacol. 1995;25:387-392.
15. Bartelstone HJ, Nasmyth PA. Vasopressin potentiation of catecholamine actions in dog, rat, cat and rat aortic strip. Am J Physiol. 1965;208:754-762.
16. Karmazyn M, Manky MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology. 1978;102:1230-1236.
17. G-nitro-L-argnine methyl ester and vasopressin in endotoxin-treated pithed rats. Eur J Pharmacol. 1992;224:63-69.
18. Hilgers KF, Veelken R, Rupprecht G, Reeh PW, Luft FC, Mann JFE. Angiotensin II facilitates sympathetic transmission in rat hind limb circulation. Hypertension. 1993;21:322-328.
19. Harada S, Imaizumi T, Momohara M, Masaki H, Ando SI, Takeshita A. Arginine vasopressin attenuates phenylephrine-induced forearm vasoconstriction in men. Clin Sci. 1991;81:733-737.
20. Medina P, Noguera I, Aldasoro M, Vila JM, Flor B, Lluch S. Enhancement by vasopressin of adrenergic responses in human mesenteric arteries. Am J Physiol. 1997;272:H1087-H1093.
21. Aldasoro M, Medina P, Vila JM, Otero E, Martínez-León JB, Lluch S. Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg. 1997;25:696-703.
22. Vlodaver Z, Edwards JE. Pathologic changes in aortic-coronary arterial saphenous vein grafts. Circulation. 1971;69:719-728.
23. Hamaker WR, O'Connel TJ, Gomez AC. Subintimal obliterative proliferation in saphenous vein grafts: a cause of early failure of aorta-to-coronary artery bypass grafts. Ann Thorac Surg. 1972;13:488-493.
24. Grondin CM, Campeau L, Lesperance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation. 1984;70(suppl I):I-208-I-212.
25. Aldasoro M, Martínez C, Vila JM, Flor B, Lluch S. Endothelium- dependent component in the contractile responses of human omental arteries to adrenergic stimulation. Eur J Pharmacol. 1993;250:103-107.
26. Doyle VM, Rüegg UT. Vasopressin induced production of inositol trisphosphate and calcium effux in a smooth muscle cell line. Biochem Biophys Res Commun. 1985;131:469-476.
27. Thibonnier M, Bayer AL, Laethem CL, Koop DR, Simonson MS. Role of eicosanoids in vasopressin-induced calcium mobilization in A7r5 vascular smooth muscle cells. Am J Physiol. 1993;265:E108-E114.
28. Altura BM, Altura BT. Vascular smooth muscle and neurohypophyseal hormones. Fed Proc. 1977;36:1853-1860.
29. Heyndrickx GR, Boettcher DH, Vatner SF. Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol. 1976;231:1579-1587.
30. García-Villalón AL, García JL, Fernandez N, Monge L, Gomez B, Dieguez G. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol. 1996;118:1848-1854.
31. Lincoln J, Loesch A, Burnstock G. Localization of vasopressin, serotonin and angiotensin II in endothelial cells of the renal and mesenteric arteries of the rat. Cell Tissue Res. 1990;259:341-344.
32. Simon JS, Brody MJ, Kasson BG. Characterization of a vasopressin-like peptide in rat and bovine blood vessels. Am J Physiol. 1992;262:H799-H805.
33. Melin B, Eclache PJ, Geelen G, Annat G, Allevard AM, Jarsaillon E, Zebidi A, Legros JJ, Gharib CI. Plasma AVP, neurophysin, renin activity, and aldosterone during submaximal exercise performed until exhaustion in trained and untrained men. Eur J Appl Physiol. 1980;44:141-151.
34. Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, Hofbauer KG, Brunner HR. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol. 1985;55:1043-1047.
35. Sorenson PS, Hammer M. Vasopressin in plasma and ventricular cerebrospinal fluid during dehydration, postural changes and nausea. Am J Physiol. 1985;17:R78-R83.
36. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol. 1986;7:758-765